AstraZeneca Covid-19 Vaccine Effectiveness Over the Elderly Questioned
The main challenge arising out of the AstraZeneca vaccine effectiveness is that only a few trial participants were of advanced age.
Justin Nzioka 
With the Covid-19 continuing wreaking havoc among nations, scientists have been working around the clock to manufacture a vaccine if not cure.
Some have already scored highly by coming up with vaccines that have shown some effectiveness to some extend, although none has managed a vaccine that can be 100% effective so far.
However, queries have now been risen over how effective one of the vaccines namely AstraZeneca is effective among those of advanced age.
Despite the European Medicines Agency maintaining that the vaccine has no proven side effects over any age bracket, some countries have warned against administering the vaccine to the elderly.
Germany has already advised against vaccinating its citizens above 65 years. At the same time, Italy has also stated that it will seek an alternative to cater to its citizens over 55 years.
France is set to decide soon on what to do with the AstraZeneca vaccine which has proven 62%. The main issue is the lack of data among the elderly trials.
AstraZeneca vaccine developers have been honest in clarifying that among the trial participants only 10% were over 65 years.
Pfizer and BioNTech trial participants had about 40% aged over 55 years. France among other nations has reportedly been giving the Pfizer and BioNTech vaccines to people as old as 80, although they are not quite sure about the effectiveness.
